|
|
|
|
| LEADER |
02978nam a2200469 4500 |
| 001 |
978-3-319-67932-7 |
| 003 |
DE-He213 |
| 005 |
20191023231231.0 |
| 007 |
cr nn 008mamaa |
| 008 |
180328s2018 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783319679327
|9 978-3-319-67932-7
|
| 024 |
7 |
|
|a 10.1007/978-3-319-67932-7
|2 doi
|
| 040 |
|
|
|d GrThAP
|
| 050 |
|
4 |
|a RC261-271
|
| 072 |
|
7 |
|a MJCL
|2 bicssc
|
| 072 |
|
7 |
|a MED062000
|2 bisacsh
|
| 072 |
|
7 |
|a MJCL
|2 thema
|
| 082 |
0 |
4 |
|a 614.5999
|2 23
|
| 245 |
1 |
0 |
|a Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
|h [electronic resource] /
|c edited by Yosef Yarden, Moshe Elkabets.
|
| 250 |
|
|
|a 1st ed. 2018.
|
| 264 |
|
1 |
|a Cham :
|b Springer International Publishing :
|b Imprint: Springer,
|c 2018.
|
| 300 |
|
|
|a XX, 242 p. 22 illus. in color.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
|
|a Resistance to Targeted Anti-Cancer Therapeutics,
|x 2196-5501 ;
|v 15
|
| 505 |
0 |
|
|a Resistance of colorectal tumors to anti-EGFR antibodies -- Resistance of lung cancer to kinase inhibitors specific to EGFR or ALK -- Mechanisms of action and resistance of trastuzumab in breast cancer -- Mechanisms of resistance to molecular therapies targeting the HGF/MET axis -- RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge -- Mechanisms of resistance to PI3K and AKT inhibitors -- Sensitivity and resistance to BH3 mimetics in cancer therapy -- Resistance mechanisms to cyclin-dependent kinase inhibitors -- Resistance to inhibitors of angiogenesis.
|
| 520 |
|
|
|a This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.
|
| 650 |
|
0 |
|a Cancer research.
|
| 650 |
1 |
4 |
|a Cancer Research.
|0 http://scigraph.springernature.com/things/product-market-codes/B11001
|
| 700 |
1 |
|
|a Yarden, Yosef.
|e editor.
|4 edt
|4 http://id.loc.gov/vocabulary/relators/edt
|
| 700 |
1 |
|
|a Elkabets, Moshe.
|e editor.
|4 edt
|4 http://id.loc.gov/vocabulary/relators/edt
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783319679303
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783319679310
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783030098179
|
| 830 |
|
0 |
|a Resistance to Targeted Anti-Cancer Therapeutics,
|x 2196-5501 ;
|v 15
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-319-67932-7
|z Full Text via HEAL-Link
|
| 912 |
|
|
|a ZDB-2-SBL
|
| 950 |
|
|
|a Biomedical and Life Sciences (Springer-11642)
|
